Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Medivir AB ( (SE:MVIR) ) just unveiled an update.
Medivir AB has appointed its Nomination Committee for the 2025–2026 period ahead of its Annual General Meeting scheduled for 7 May 2026. The committee comprises Board Chairman Anders Hallberg, appointed by Hallberg Management AB, Karl Tobieson of Linc AB, and Johan Claesson, representing CA Fastigheter AB and himself, with Tobieson named Chair of the Nomination Committee, underscoring the continued influence of the company’s largest shareholders over board composition and governance as Medivir advances its oncology-focused pipeline.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a Swedish pharmaceutical company specializing in the development of innovative cancer treatments targeting indications with high unmet medical need, particularly where existing therapies are limited or absent. Its lead drug candidate, fostroxacitabine bralpamide (fostrox), is designed for the selective treatment of liver cancer with reduced side effects, and the company pursues its R&D both independently and through partnerships. Medivir’s shares trade on Nasdaq Stockholm’s Small Cap list.
Average Trading Volume: 1,248,976
Technical Sentiment Signal: Sell
Current Market Cap: SEK224.3M
Find detailed analytics on MVIR stock on TipRanks’ Stock Analysis page.